

# Hematological Malignancy Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/H6402AF35A4DEN.html>

Date: July 2022

Pages: 103

Price: US\$ 3,250.00 (Single User License)

ID: H6402AF35A4DEN

## Abstracts

This report contains market size and forecasts of Hematological Malignancy Treatment in Global, including the following market information:

Global Hematological Malignancy Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Hematological Malignancy Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Monoclonal Antibody Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hematological Malignancy Treatment include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hematological Malignancy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers,

challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hematological Malignancy Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Hematological Malignancy Treatment Market Segment Percentages, by Type, 2021 (%)

Monoclonal Antibody

Immunomodulatory Drug

Tyrosine Kinase Inhibitor

Proteasome Inhibitors

Others

Global Hematological Malignancy Treatment Market, by Indication, 2017-2022, 2023-2028 (\$ millions)

Global Hematological Malignancy Treatment Market Segment Percentages, by Indication, 2021 (%)

ALL

CLL

AML

NHL

DLBCL

MM

Others

Global Hematological Malignancy Treatment Market, By Region and Country,  
2017-2022, 2023-2028 (\$ Millions)

Global Hematological Malignancy Treatment Market Segment Percentages, By Region  
and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hematological Malignancy Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Hematological Malignancy Treatment revenues share in global market,

2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Sanofi

Bayer

Biogen Idec

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Hematological Malignancy Treatment Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Indication
- 1.3 Global Hematological Malignancy Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL HEMATOLOGICAL MALIGNANCY TREATMENT OVERALL MARKET SIZE**

- 2.1 Global Hematological Malignancy Treatment Market Size: 2021 VS 2028
- 2.2 Global Hematological Malignancy Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Hematological Malignancy Treatment Players in Global Market
- 3.2 Top Global Hematological Malignancy Treatment Companies Ranked by Revenue
- 3.3 Global Hematological Malignancy Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Hematological Malignancy Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Hematological Malignancy Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Hematological Malignancy Treatment Players in Global Market
  - 3.6.1 List of Global Tier 1 Hematological Malignancy Treatment Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 Hematological Malignancy Treatment Companies

## **4 MARKET SIGHTS BY PRODUCT**

### 4.1 Overview

4.1.1 by Type - Global Hematological Malignancy Treatment Market Size Markets, 2021 & 2028

4.1.2 Monoclonal Antibody

4.1.3 Immunomodulatory Drug

4.1.4 Tyrosine Kinase Inhibitor

4.1.5 Proteasome Inhibitors

4.1.6 Others

4.2 By Type - Global Hematological Malignancy Treatment Revenue & Forecasts

4.2.1 By Type - Global Hematological Malignancy Treatment Revenue, 2017-2022

4.2.2 By Type - Global Hematological Malignancy Treatment Revenue, 2023-2028

4.2.3 By Type - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028

## **5 SIGHTS BY APPLICATION**

### 5.1 Overview

5.1.1 By Application - Global Hematological Malignancy Treatment Market Size, 2021 & 2028

5.1.2 ALL

5.1.3 CLL

5.1.4 AML

5.1.5 NHL

5.1.6 DLBCL

5.1.7 MM

5.1.8 Others

5.2 By Indication - Global Hematological Malignancy Treatment Revenue & Forecasts

5.2.1 By Indication - Global Hematological Malignancy Treatment Revenue, 2017-2022

5.2.2 By Indication - Global Hematological Malignancy Treatment Revenue, 2023-2028

5.2.3 By Indication - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028

## **6 SIGHTS BY REGION**

6.1 By Region - Global Hematological Malignancy Treatment Market Size, 2021 & 2028

6.2 By Region - Global Hematological Malignancy Treatment Revenue & Forecasts

- 6.2.1 By Region - Global Hematological Malignancy Treatment Revenue, 2017-2022
- 6.2.2 By Region - Global Hematological Malignancy Treatment Revenue, 2023-2028
- 6.2.3 By Region - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028
- 6.3 North America
  - 6.3.1 By Country - North America Hematological Malignancy Treatment Revenue, 2017-2028
  - 6.3.2 US Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.3.3 Canada Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.3.4 Mexico Hematological Malignancy Treatment Market Size, 2017-2028
- 6.4 Europe
  - 6.4.1 By Country - Europe Hematological Malignancy Treatment Revenue, 2017-2028
  - 6.4.2 Germany Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.4.3 France Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.4.4 U.K. Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.4.5 Italy Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.4.6 Russia Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.4.7 Nordic Countries Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.4.8 Benelux Hematological Malignancy Treatment Market Size, 2017-2028
- 6.5 Asia
  - 6.5.1 By Region - Asia Hematological Malignancy Treatment Revenue, 2017-2028
  - 6.5.2 China Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.5.3 Japan Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.5.4 South Korea Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.5.5 Southeast Asia Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.5.6 India Hematological Malignancy Treatment Market Size, 2017-2028
- 6.6 South America
  - 6.6.1 By Country - South America Hematological Malignancy Treatment Revenue, 2017-2028
  - 6.6.2 Brazil Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.6.3 Argentina Hematological Malignancy Treatment Market Size, 2017-2028
- 6.7 Middle East & Africa
  - 6.7.1 By Country - Middle East & Africa Hematological Malignancy Treatment Revenue, 2017-2028
  - 6.7.2 Turkey Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.7.3 Israel Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.7.4 Saudi Arabia Hematological Malignancy Treatment Market Size, 2017-2028
  - 6.7.5 UAE Hematological Malignancy Treatment Market Size, 2017-2028



## 7 PLAYERS PROFILES

### 7.1 Roche

7.1.1 Roche Corporate Summary

7.1.2 Roche Business Overview

7.1.3 Roche Hematological Malignancy Treatment Major Product Offerings

7.1.4 Roche Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.1.5 Roche Key News

### 7.2 Celgene

7.2.1 Celgene Corporate Summary

7.2.2 Celgene Business Overview

7.2.3 Celgene Hematological Malignancy Treatment Major Product Offerings

7.2.4 Celgene Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.2.5 Celgene Key News

### 7.3 Novartis

7.3.1 Novartis Corporate Summary

7.3.2 Novartis Business Overview

7.3.3 Novartis Hematological Malignancy Treatment Major Product Offerings

7.3.4 Novartis Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.3.5 Novartis Key News

### 7.4 Bristol-Myers Squibb

7.4.1 Bristol-Myers Squibb Corporate Summary

7.4.2 Bristol-Myers Squibb Business Overview

7.4.3 Bristol-Myers Squibb Hematological Malignancy Treatment Major Product Offerings

7.4.4 Bristol-Myers Squibb Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.4.5 Bristol-Myers Squibb Key News

### 7.5 Johnson & Johnson

7.5.1 Johnson & Johnson Corporate Summary

7.5.2 Johnson & Johnson Business Overview

7.5.3 Johnson & Johnson Hematological Malignancy Treatment Major Product Offerings

7.5.4 Johnson & Johnson Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.5.5 Johnson & Johnson Key News

## 7.6 Merck & Co.

7.6.1 Merck & Co. Corporate Summary

7.6.2 Merck & Co. Business Overview

7.6.3 Merck & Co. Hematological Malignancy Treatment Major Product Offerings

7.6.4 Merck & Co. Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.6.5 Merck & Co. Key News

## 7.7 AstraZeneca

7.7.1 AstraZeneca Corporate Summary

7.7.2 AstraZeneca Business Overview

7.7.3 AstraZeneca Hematological Malignancy Treatment Major Product Offerings

7.7.4 AstraZeneca Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.7.5 AstraZeneca Key News

## 7.8 Pfizer

7.8.1 Pfizer Corporate Summary

7.8.2 Pfizer Business Overview

7.8.3 Pfizer Hematological Malignancy Treatment Major Product Offerings

7.8.4 Pfizer Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.8.5 Pfizer Key News

## 7.9 Amgen

7.9.1 Amgen Corporate Summary

7.9.2 Amgen Business Overview

7.9.3 Amgen Hematological Malignancy Treatment Major Product Offerings

7.9.4 Amgen Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.9.5 Amgen Key News

## 7.10 Eli Lilly

7.10.1 Eli Lilly Corporate Summary

7.10.2 Eli Lilly Business Overview

7.10.3 Eli Lilly Hematological Malignancy Treatment Major Product Offerings

7.10.4 Eli Lilly Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.10.5 Eli Lilly Key News

## 7.11 AbbVie

7.11.1 AbbVie Corporate Summary

7.11.2 AbbVie Business Overview

7.11.3 AbbVie Hematological Malignancy Treatment Major Product Offerings

7.11.4 AbbVie Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.11.5 AbbVie Key News

7.12 Takeda

7.12.1 Takeda Corporate Summary

7.12.2 Takeda Business Overview

7.12.3 Takeda Hematological Malignancy Treatment Major Product Offerings

7.12.4 Takeda Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.12.5 Takeda Key News

7.13 Sanofi

7.13.1 Sanofi Corporate Summary

7.13.2 Sanofi Business Overview

7.13.3 Sanofi Hematological Malignancy Treatment Major Product Offerings

7.13.4 Sanofi Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.13.5 Sanofi Key News

7.14 Bayer

7.14.1 Bayer Corporate Summary

7.14.2 Bayer Business Overview

7.14.3 Bayer Hematological Malignancy Treatment Major Product Offerings

7.14.4 Bayer Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.14.5 Bayer Key News

7.15 Biogen Idec

7.15.1 Biogen Idec Corporate Summary

7.15.2 Biogen Idec Business Overview

7.15.3 Biogen Idec Hematological Malignancy Treatment Major Product Offerings

7.15.4 Biogen Idec Hematological Malignancy Treatment Revenue in Global Market (2017-2022)

7.15.5 Biogen Idec Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer



## List Of Tables

### LIST OF TABLES

Table 1. Hematological Malignancy Treatment Market Opportunities & Trends in Global Market

Table 2. Hematological Malignancy Treatment Market Drivers in Global Market

Table 3. Hematological Malignancy Treatment Market Restraints in Global Market

Table 4. Key Players of Hematological Malignancy Treatment in Global Market

Table 5. Top Hematological Malignancy Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Hematological Malignancy Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Hematological Malignancy Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Hematological Malignancy Treatment Product Type

Table 9. List of Global Tier 1 Hematological Malignancy Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Hematological Malignancy Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Hematological Malignancy Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Hematological Malignancy Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Hematological Malignancy Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Indication – Global Hematological Malignancy Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Indication - Hematological Malignancy Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Indication - Hematological Malignancy Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Hematological Malignancy Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Hematological Malignancy Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Hematological Malignancy Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Hematological Malignancy Treatment Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Hematological Malignancy Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hematological Malignancy Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hematological Malignancy Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hematological Malignancy Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hematological Malignancy Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Roche Corporate Summary

Table 31. Roche Hematological Malignancy Treatment Product Offerings

Table 32. Roche Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Celgene Corporate Summary

Table 34. Celgene Hematological Malignancy Treatment Product Offerings

Table 35. Celgene Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Novartis Corporate Summary

Table 37. Novartis Hematological Malignancy Treatment Product Offerings

Table 38. Novartis Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Bristol-Myers Squibb Corporate Summary

Table 40. Bristol-Myers Squibb Hematological Malignancy Treatment Product Offerings

Table 41. Bristol-Myers Squibb Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Johnson & Johnson Corporate Summary

Table 43. Johnson & Johnson Hematological Malignancy Treatment Product Offerings

Table 44. Johnson & Johnson Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)

- Table 45. Merck & Co. Corporate Summary
- Table 46. Merck & Co. Hematological Malignancy Treatment Product Offerings
- Table 47. Merck & Co. Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 48. AstraZeneca Corporate Summary
- Table 49. AstraZeneca Hematological Malignancy Treatment Product Offerings
- Table 50. AstraZeneca Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 51. Pfizer Corporate Summary
- Table 52. Pfizer Hematological Malignancy Treatment Product Offerings
- Table 53. Pfizer Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 54. Amgen Corporate Summary
- Table 55. Amgen Hematological Malignancy Treatment Product Offerings
- Table 56. Amgen Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 57. Eli Lilly Corporate Summary
- Table 58. Eli Lilly Hematological Malignancy Treatment Product Offerings
- Table 59. Eli Lilly Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 60. AbbVie Corporate Summary
- Table 61. AbbVie Hematological Malignancy Treatment Product Offerings
- Table 62. AbbVie Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 63. Takeda Corporate Summary
- Table 64. Takeda Hematological Malignancy Treatment Product Offerings
- Table 65. Takeda Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 66. Sanofi Corporate Summary
- Table 67. Sanofi Hematological Malignancy Treatment Product Offerings
- Table 68. Sanofi Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 69. Bayer Corporate Summary
- Table 70. Bayer Hematological Malignancy Treatment Product Offerings
- Table 71. Bayer Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)
- Table 72. Biogen Idec Corporate Summary
- Table 73. Biogen Idec Hematological Malignancy Treatment Product Offerings
- Table 74. Biogen Idec Hematological Malignancy Treatment Revenue (US\$, Mn), (2017-2022)



## List Of Figures

### LIST OF FIGURES

Figure 1. Hematological Malignancy Treatment Segment by Type in 2021

Figure 2. Hematological Malignancy Treatment Segment by Indication in 2021

Figure 3. Global Hematological Malignancy Treatment Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Hematological Malignancy Treatment Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Hematological Malignancy Treatment Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Hematological Malignancy Treatment Revenue in 2021

Figure 8. By Type - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 9. By Indication - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 10. By Region - Global Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 11. By Country - North America Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 12. US Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 16. Germany Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 17. France Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Hematological Malignancy Treatment Revenue, (US\$, Mn),



2017-2028

Figure 23. By Region - Asia Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 24. China Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hematological Malignancy Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hematological Malignancy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Roche Hematological Malignancy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Celgene Hematological Malignancy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Novartis Hematological Malignancy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Bristol-Myers Squibb Hematological Malignancy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Johnson & Johnson Hematological Malignancy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Merck & Co. Hematological Malignancy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. AstraZeneca Hematological Malignancy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Pfizer Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

Figure 45. Amgen Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

Figure 46. Eli Lilly Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

Figure 47. AbbVie Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

Figure 48. Takeda Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

Figure 49. Sanofi Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

Figure 50. Bayer Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

Figure 51. Biogen Idec Hematological Malignancy Treatment Revenue Year Over Year

Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Hematological Malignancy Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/H6402AF35A4DEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H6402AF35A4DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970